ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer

Abstract 

Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide, and metastatic colorectal cancer (mCRC) remains a challenging clinical entity. The Alliance for Clinical Trials in Oncology (Alliance) A022101/NRG-GI009 trial, also known as the Evaluating Radiation, Ablation, and Surgery (ERASur) study, aims to determine whether the addition of total ablative therapy (TAT) to standard systemic treatment can enhance overall survival (OS) in patients with limited metastatic CRC. The trial specifically targets patients with up to four metastatic lesions, excluding those with liver-only disease, and mandates that all metastatic sites be amenable to ablation via surgical resection, microwave ablation, or stereotactic ablative body radiotherapy (SABR). This phase III randomized study will enroll 346 patients to provide robust data on the impact of TAT in addition to systemic therapy. Key secondary endpoints include event-free survival, adverse event profiles, and time to local recurrence. The study promises to offer crucial insights into the evolving role of metastatic-directed therapies in patients with limited mCRC and could redefine treatment strategies for this population.

Introduction 

Metastatic colorectal cancer (mCRC) is one of the leading causes of cancer-related deaths, with a substantial number of patients presenting with metastatic disease at diagnosis. While systemic therapies have improved survival outcomes, patients with liver-confined or limited metastatic disease may benefit from localized treatments. Historically, liver-directed therapies, such as surgical resection or ablation, have demonstrated favorable outcomes in selected patients with liver-only metastases. However, the efficacy of local therapy in patients with more advanced mCRC, including those with extrahepatic disease, remains unclear. The ERASur trial addresses this knowledge gap by evaluating the role of total ablative therapy (TAT) in combination with standard systemic therapy for patients with newly diagnosed limited mCRC.

Patients eligible for the ERASur trial are required to have a pathological diagnosis of colorectal cancer, BRAF wild-type and microsatellite stable disease, and up to four metastatic lesions. Importantly, liver-only metastatic disease is excluded, and all metastatic lesions must be amenable to local ablative treatment. The trial incorporates a pragmatic design, randomizing patients to either continuation of systemic therapy alone or systemic therapy plus TAT, which includes surgical resection, microwave ablation, or SABR. The primary endpoint of the trial is overall survival (OS), with secondary endpoints including event-free survival, adverse event profiles, and time to local recurrence.

The rationale for the ERASur trial is rooted in the potential benefits of combining local ablative treatments with systemic therapy in mCRC. By targeting and eliminating limited metastatic lesions, TAT may provide improved local control and potentially delay the onset of systemic progression, thereby extending OS. This trial aims to clarify the role of metastatic-directed therapy in patients with limited mCRC and may ultimately guide treatment decisions for this patient population.

Literature Review

Colorectal cancer is a prevalent malignancy with high morbidity and mortality rates, particularly in the context of metastatic disease. Approximately 20-25% of CRC patients present with metastases at the time of diagnosis, and metastatic colorectal cancer (mCRC) is associated with poor prognosis despite advancements in systemic therapies. For patients with liver-confined metastases, surgical resection or local ablation offers the potential for long-term survival, with five-year survival rates of up to 40-50% in selected cases. However, the role of local therapy in patients with more extensive or extrahepatic metastatic disease remains less well-defined.

Several studies have evaluated the role of localized treatment in mCRC. The EORTC 40983 study demonstrated that perioperative chemotherapy combined with liver resection improved progression-free survival in patients with resectable liver metastases compared to surgery alone. Similarly, the CLOCC trial showed that radiofrequency ablation (RFA) combined with systemic chemotherapy led to improved progression-free survival and overall survival in patients with unresectable liver metastases. These studies highlight the potential benefits of local therapy in patients with liver-confined disease.

However, the efficacy of local ablative treatments in patients with more advanced mCRC, including those with extrahepatic disease, remains a subject of debate. The potential benefit of combining local ablative treatments with systemic therapy lies in the ability to achieve better local control of metastatic lesions, delay systemic progression, and ultimately improve survival outcomes. The ERASur trial seeks to address this knowledge gap by evaluating the addition of total ablative therapy (TAT) to standard systemic therapy in patients with limited mCRC.

The ERASur trial is particularly relevant in the context of recent advancements in ablative technologies, such as microwave ablation and stereotactic ablative body radiotherapy (SABR). SABR, in particular, has gained attention for its ability to deliver high-dose radiation with precision, minimizing damage to surrounding tissues and allowing for effective treatment of metastatic lesions. Multiple studies have shown the safety and efficacy of SABR in treating oligometastatic disease in various cancers, including colorectal cancer. Microwave ablation, another modality evaluated in the ERASur trial, has also demonstrated efficacy in treating hepatic and extrahepatic metastases, offering a minimally invasive alternative to surgical resection.

Despite these promising developments, there remains a lack of high-quality evidence from randomized controlled trials evaluating the role of TAT in patients with limited mCRC. The ERASur trial seeks to fill this gap by providing robust data on the impact of TAT in combination with systemic therapy. The trial's pragmatic design and inclusion of various ablative modalities make it a valuable study in understanding the evolving role of local therapies in mCRC.

In conclusion, the ERASur trial addresses an important clinical question regarding the role of total ablative therapy in patients with limited mCRC. The results of this trial have the potential to inform clinical practice and guide treatment decisions for this patient population. If successful, the ERASur trial could pave the way for a new standard of care that integrates local ablative treatments with systemic therapy in selected patients with metastatic colorectal cancer.

Methodology

The Evaluating Radiation, Ablation, and Surgery (ERASur) trial (A022101/NRG-GI009) is a National Cancer Institute-sponsored, phase III randomized study that seeks to assess whether adding total ablative therapy (TAT) to standard-of-care systemic therapy improves overall survival (OS) in patients with newly diagnosed limited metastatic colorectal cancer (mCRC). The trial's design reflects the growing interest in incorporating local therapies into the treatment regimen for metastatic cancer patients.

Eligibility Criteria

Patients eligible for enrollment in the ERASur trial must meet the following inclusion criteria:

1. Pathological Confirmation: A confirmed diagnosis of colorectal cancer (CRC) is required.

2. Molecular Profile: Patients must have BRAF wild-type and microsatellite stable (MSS) disease, which are common molecular characteristics associated with colorectal cancer prognosis and treatment response.

3. Extent of Disease: Only patients with four or fewer metastatic lesions are eligible, ensuring that the metastatic burden is limited. However, patients with liver-only metastatic disease are excluded.

4. Ablation Feasibility: All identified metastatic lesions must be amenable to total ablative therapy (TAT), which includes surgical resection, microwave ablation, and/or stereotactic ablative body radiotherapy (SABR). This ensures that the lesions can be targeted effectively by local therapies.

Treatment Protocol

Eligible patients will receive first-line systemic therapy for 16 to 26 weeks. After completion of this induction phase, patients who do not show overt disease progression will be randomized 1:1 into two arms:

1. Arm A (Control Group): Continuation of systemic therapy alone without any local ablative interventions.

2. Arm B (Experimental Group): Continuation of systemic therapy along with TAT, which may include surgical resection, microwave ablation, and/or SABR. SABR is required for at least one metastatic lesion, highlighting its role in treating oligometastatic disease.

The trial's design ensures that TAT is only applied to patients who achieve stability on systemic therapy. This approach mitigates the risk of local treatment in patients with rapidly progressing disease, where systemic control may be more crucial.

Study Endpoints

The primary endpoint of the ERASur trial is overall survival (OS). Secondary endpoints include:

• Event-Free Survival (EFS): Measuring the time to disease progression or death.

• Adverse Event Profile: Documenting the safety and tolerability of the interventions, particularly TAT, which can involve significant risk depending on the location and number of metastatic lesions.

• Time to Local Recurrence: Assessing the efficacy of TAT in preventing local recurrences at treated metastatic sites.

• Exploratory Biomarker Analyses: Investigating potential biomarkers that may predict response to TAT and guide future personalized treatment strategies.

The trial employs a group sequential design with two interim analyses for futility, providing opportunities for early assessment of treatment efficacy and safety. The trial aims to enroll 346 patients, providing 80% power to detect an improvement in OS from a median of 26 months in the control arm to 37 months in the experimental arm, with a hazard ratio (HR) of 0.7.

Statistical Analysis

The statistical design of the ERASur trial follows standard methodologies for phase III oncology studies. A log-rank test will be used to compare OS between the two arms, with a one-sided alpha of 0.05. Cox proportional hazards models will be employed to adjust for potential confounders and perform subgroup analyses based on factors such as molecular characteristics, number and location of metastatic lesions, and type of ablative therapy used.

Secondary endpoints will be analyzed using Kaplan-Meier survival curves, and comparisons will be made using log-rank tests and Cox models. Adverse events will be categorized and compared using chi-square or Fisher's exact tests, as appropriate. Time to local recurrence will be evaluated using competing risks models to account for the potential confounding effect of death on recurrence outcomes.

Results

The ERASur trial is ongoing, and final results have yet to be published. However, early interim analyses will provide initial insights into the efficacy and safety of adding TAT to systemic therapy in patients with limited mCRC.

Previous studies investigating local therapies in mCRC have shown promising results in terms of progression-free survival (PFS) and OS. The EORTC 40983 study, for example, demonstrated that perioperative chemotherapy combined with liver resection improved PFS in patients with resectable liver metastases. Similarly, the CLOCC trial showed that radiofrequency ablation (RFA) combined with systemic chemotherapy improved PFS and OS in patients with unresectable liver metastases.

These studies highlight the potential benefits of local therapy in selected mCRC patients, particularly those with liver-confined disease. However, the ERASur trial extends this concept to patients with limited metastatic disease outside the liver, providing a broader evaluation of TAT in mCRC.

If the final results of the ERASur trial show a significant improvement in OS with the addition of TAT, this could have major implications for the management of mCRC, potentially expanding the use of local therapies beyond liver metastases.

Conclusion

The ERASur trial represents a pivotal study in the field of metastatic colorectal cancer (mCRC), addressing an important clinical question regarding the role of total ablative therapy (TAT) in patients with limited metastatic disease. By evaluating the combination of TAT with standard systemic therapy, the trial seeks to determine whether this approach can improve overall survival (OS) in patients with newly diagnosed limited mCRC.

Local ablative therapies, including surgical resection, microwave ablation, and stereotactic ablative body radiotherapy (SABR), have shown promise in treating metastatic lesions in various cancers, including colorectal cancer. However, their role in patients with more extensive metastatic disease, including those with extrahepatic metastases, remains less clear. The ERASur trial will provide robust data to clarify the efficacy and safety of TAT in this patient population.

If successful, the ERASur trial could lead to a paradigm shift in the treatment of mCRC, incorporating local therapies into the standard treatment regimen for patients with limited metastatic disease. This would represent a significant advancement in the management of mCRC, offering new hope for patients with this challenging condition.

Discussion

The rationale behind the ERASur trial stems from the evolving understanding of metastatic colorectal cancer as a heterogeneous disease. Traditionally, patients with metastatic disease were treated with systemic therapy alone, as the metastatic burden was considered too diffuse for local interventions. However, advances in imaging, surgical techniques, and ablative technologies have led to the concept of oligometastatic disease—a state where the metastatic burden is limited and potentially curable with aggressive local therapies.

The ERASur trial builds on this concept by targeting patients with up to four metastatic lesions, all of which must be amenable to local treatment. This approach recognizes that some patients with limited metastatic disease may benefit from more aggressive local treatment, in addition to systemic therapy, to achieve long-term disease control.

One of the key strengths of the ERASur trial is its pragmatic design, which allows for the use of various ablative modalities, including surgery, microwave ablation, and SABR. This flexibility reflects real-world clinical practice, where treatment decisions are often based on the size, location, and number of metastatic lesions, as well as the patient’s overall health and preferences.

The trial’s focus on SABR is particularly noteworthy, as this technology has gained popularity for its ability to deliver high-dose radiation with precision, minimizing damage to surrounding tissues. SABR has shown promise in treating oligometastatic disease in various cancers, including colorectal cancer, and its inclusion in the ERASur trial highlights its potential role in the management of mCRC.

Despite these strengths, the ERASur trial also faces challenges. One of the key challenges is patient selection. While the trial’s inclusion criteria are designed to identify patients with limited metastatic disease who are most likely to benefit from local therapy, there remains a risk that some patients may develop more extensive metastatic disease over time, making them less suitable for TAT. This underscores the importance of careful patient selection and the need for ongoing monitoring and evaluation of disease progression throughout the trial.

Another challenge is the potential for adverse events associated with local therapies. While TAT is generally well-tolerated, there is a risk of complications, particularly with more invasive procedures such as surgery. The ERASur trial will carefully monitor and document these adverse events to ensure that the benefits of TAT outweigh the risks.

Future Prospects

The future prospects of the ERASur trial are significant, with the potential to redefine the management of metastatic colorectal cancer. If the trial demonstrates a significant improvement in overall survival with the addition of total ablative therapy (TAT), this could lead to a new standard of care for patients with limited metastatic colorectal cancer.

In addition to its impact on clinical practice, the ERASur trial could also pave the way for further research into the role of local therapies in other metastatic cancers. The concept of oligometastatic disease is not unique to colorectal cancer, and similar trials could be conducted in other cancers, such as lung, breast, and prostate cancer, where local therapies may play a role in the management of limited metastatic disease.

The trial’s exploratory biomarker analyses could also provide valuable insights into the molecular characteristics of patients who are most likely to benefit from TAT. By identifying predictive biomarkers, future trials could focus on personalized treatment strategies, tailoring local therapies to the individual patient’s molecular profile.

Finally, the ERASur trial highlights the importance of multidisciplinary care in the management of metastatic cancer. The trial’s use of various ablative modalities, including surgery, microwave ablation, and SABR, underscores the need for close collaboration between medical oncologists, radiation oncologists, and surgical oncologists. This multidisciplinary approach is critical for optimizing patient outcomes and ensuring that treatment decisions are based on a comprehensive understanding of both the systemic and local aspects of metastatic disease.

The ERASur trial could serve as a model for future clinical trials that explore the integration of systemic and local therapies in the treatment of metastatic cancer. With advancements in technology, the precision of local therapies like stereotactic ablative body radiotherapy (SABR) will continue to improve, potentially allowing for even more targeted interventions with reduced risk of adverse effects.

Integration of New Technologies

As new ablative technologies and radiotherapy techniques emerge, there will be opportunities to refine treatment strategies for metastatic colorectal cancer (mCRC). For instance, advances in imaging may improve the identification of patients who are most likely to benefit from total ablative therapy (TAT) by providing more detailed assessments of tumor burden and locations. Additionally, developments in artificial intelligence (AI) and machine learning could enhance treatment planning by optimizing the delivery of radiation and ablative therapies based on individualized patient data.

Personalized Medicine and Biomarkers

The exploration of biomarkers in the ERASur trial represents an important step toward personalized medicine in mCRC. By identifying patients whose molecular profiles suggest a favorable response to TAT, future clinical trials may be able to tailor local and systemic therapies to maximize survival benefits. This could lead to more precise and effective treatments, reducing the burden of unnecessary or ineffective interventions for patients with less favorable profiles.

As biomarker research advances, the goal of precision oncology—where treatment is customized based on the genetic and molecular characteristics of a patient’s tumor—may become a reality for more patients with metastatic cancer.

Conclusion

The ERASur trial represents a critical exploration into the role of total ablative therapy (TAT) in metastatic colorectal cancer, addressing the important question of whether adding local interventions to standard systemic therapy can improve outcomes for patients with limited metastatic disease. By focusing on overall survival (OS) as the primary endpoint, the trial aims to provide robust evidence on the efficacy of combining local and systemic therapies in mCRC.

The future prospects of this trial extend beyond colorectal cancer, with potential applications in other metastatic cancers where local therapies could play a role in disease control. As the results of the ERASur trial unfold, they will likely shape future research and clinical practice, contributing to the ongoing evolution of cancer treatment strategies that integrate local and systemic approaches.

Ultimately, if successful, the ERASur trial could lead to significant changes in the treatment paradigm for metastatic colorectal cancer, offering new hope for patients and further advancing the field of oncology.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors